Anika Therapeutics Inc
NASDAQ:ANIK
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
16.3
28.75
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ANIK stock under the Base Case scenario is 15.03 USD. Compared to the current market price of 16.77 USD, Anika Therapeutics Inc is Overvalued by 10%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Anika Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ANIK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Anika Therapeutics Inc
Balance Sheet Decomposition
Anika Therapeutics Inc
Current Assets | 136.1m |
Cash & Short-Term Investments | 62.4m |
Receivables | 28.4m |
Other Current Assets | 45.4m |
Non-Current Assets | 95.3m |
PP&E | 71.8m |
Intangibles | 10.7m |
Other Non-Current Assets | 12.8m |
Current Liabilities | 25.5m |
Accounts Payable | 6.8m |
Accrued Liabilities | 18.7m |
Non-Current Liabilities | 26m |
Other Non-Current Liabilities | 26m |
Earnings Waterfall
Anika Therapeutics Inc
Revenue
|
164.2m
USD
|
Cost of Revenue
|
-83.9m
USD
|
Gross Profit
|
80.2m
USD
|
Operating Expenses
|
-109.6m
USD
|
Operating Income
|
-29.3m
USD
|
Other Expenses
|
-68.2m
USD
|
Net Income
|
-97.5m
USD
|
Free Cash Flow Analysis
Anika Therapeutics Inc
USD | |
Free Cash Flow | USD |
ANIK Profitability Score
Profitability Due Diligence
Anika Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Anika Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
ANIK Solvency Score
Solvency Due Diligence
Anika Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Anika Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANIK Price Targets Summary
Anika Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for ANIK is 35.19 USD with a low forecast of 32.32 USD and a high forecast of 38.85 USD.
Dividends
Current shareholder yield for ANIK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.
Contact
IPO
Employees
Officers
The intrinsic value of one ANIK stock under the Base Case scenario is 15.03 USD.
Compared to the current market price of 16.77 USD, Anika Therapeutics Inc is Overvalued by 10%.